These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 15496216

  • 21. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J, Dodd S, Durkin M, Sloan S.
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [Abstract] [Full Text] [Related]

  • 22. Proton pump inhibitors: an update.
    Vanderhoff BT, Tahboub RM.
    Am Fam Physician; 2002 Jul 15; 66(2):273-80. PubMed ID: 12152963
    [Abstract] [Full Text] [Related]

  • 23. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M, Manno M, De Micheli E, Savarino V.
    Dig Liver Dis; 2006 Feb 15; 38(2):85-90. PubMed ID: 16289976
    [Abstract] [Full Text] [Related]

  • 24. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW, Goh KL, Wong BC.
    J Gastroenterol Hepatol; 2005 Dec 15; 20 Suppl():S22-8. PubMed ID: 16359346
    [Abstract] [Full Text] [Related]

  • 25. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW, Goh KL.
    J Gastroenterol Hepatol; 2004 Sep 15; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [Abstract] [Full Text] [Related]

  • 26. Review article: is stringent control of gastric pH useful and practical in GERD?
    Kahrilas PJ.
    Aliment Pharmacol Ther; 2004 Oct 15; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
    [Abstract] [Full Text] [Related]

  • 27. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD, Sloan S, Robinson M, Miner PB.
    Aliment Pharmacol Ther; 2004 Dec 15; 20(11-12):1381-6. PubMed ID: 15606401
    [Abstract] [Full Text] [Related]

  • 28. Lansoprazole: a comprehensive review.
    Zimmermann AE, Katona BG.
    Pharmacotherapy; 1997 Dec 15; 17(2):308-26. PubMed ID: 9085323
    [Abstract] [Full Text] [Related]

  • 29. Shortcomings of the first-generation proton pump inhibitors.
    Tytgat GN.
    Eur J Gastroenterol Hepatol; 2001 May 15; 13 Suppl 1():S29-33. PubMed ID: 11430506
    [Abstract] [Full Text] [Related]

  • 30. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A, Mignon M, Samoyeau R.
    Gastroenterol Clin Biol; 2002 Apr 15; 26(4):355-9. PubMed ID: 12070410
    [Abstract] [Full Text] [Related]

  • 31. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec 15; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 32. [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
    Morozov SV, Tsodikova OM, Isakov VA, Tereshchenko SG, Gushchin AE, Shipulin GA.
    Ter Arkh; 2005 Dec 15; 77(2):21-5. PubMed ID: 15807445
    [Abstract] [Full Text] [Related]

  • 33. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct 15; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 34. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR.
    Aliment Pharmacol Ther; 2006 Mar 15; 23 Suppl 1():33-9. PubMed ID: 16483268
    [Abstract] [Full Text] [Related]

  • 35. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Mar 15; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 36. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM, Vitols S.
    Lakartidningen; 2003 Jun 19; 100(25):2212-6. PubMed ID: 12872509
    [Abstract] [Full Text] [Related]

  • 37. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M.
    Eur J Gastroenterol Hepatol; 2001 May 19; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [Abstract] [Full Text] [Related]

  • 38. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar 19; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 39. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
    Armstrong D.
    Aliment Pharmacol Ther; 2004 Oct 19; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
    [Abstract] [Full Text] [Related]

  • 40. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB.
    Aliment Pharmacol Ther; 2006 Mar 19; 23 Suppl 1():25-32. PubMed ID: 16483267
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.